Efficacy and metabolic effects of lurasidone versus brexpiprazole in schizophrenia: a network meta-analysis

Written by Daisy Ng-Mak, Vanita Tongbram, Kerigo Ndirangu, Krithika Rajagopalan & Antony Loebel

Currently, there are no head-to-head trials comparing the efficacy and metabolic parameters of lurasidone and brexpiprazole for patients with acute schizophrenia. Daisy Ng-Mak and colleagues conducted a network meta-analysis to address this important question. Read the abstract below to find out more on this study, or read the full-text article in Journal of Comparative Effectiveness Research here.
Aim: To assess the relative efficacy and metabolic effects of lurasidone and brexpiprazole in the acute treatment of schizophrenia. Methods: Five lurasidone and three brexpiprazole trials were identified. In the absence of head-to-head trials, a Bayesian network meta-analysis comparing lurasidone and brexpiprazole was performed. Results: Nonstatistically significant differences in efficacy measures were observed between lurasidone and brexpiprazole. Significant differences favoring lurasidone for weight change (-0.69 kg; 95% CrI: -1.22 to -0.15), total cholesterol (-7.60 mg/dl; 95% CrI: -13.94 to -1.22), and low-density lipoprotein (-6.58 mg/dl; 95% CrI: -12.11 to -1.04) were observed, with a trend indicating half the risk of experience ≥7% weight gain. Conclusion: This network meta-analysis suggested that lurasidone had similar efficacy and fewer metabolic effects than brexpiprazole in patients with acute schizophrenia.

Click here to read the full article from Journal of Comparative Effectiveness Research.